Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1

作者：

Villegas, Ana ^{[1
]}

Arrizabalaga, B. ^{[2
]}

Fernandez-lago, C. ^{[3
]}

Mouzo, M. ^{[4
]}

Mayans, Jr ^{[5
]}

Gonalez-Porras, Jr ^{[6
]}

Duarte, Rafael ^{[7
]}

Remacha, Angel Francisco ^{[8
]}

Luno, Elisa ^{[9
]}

Gasquet, J. A.

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Hosp Cruces, Dept Haematol, Bilbao, Spain

[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain

[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain

[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain

[6] Hosp Univ Salamanca, Salamanca, Spain

[7] Hosp Duran & Reynals ICO, Bellvitge, Spain

[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[9] Hosp Univ Cent Asturias, Oviedo, Spain

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

10.1182/blood.V112.11.3451.3451

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1184 / 1184

页数：1

共 50 条

[31] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes [J].

Garcia-Manero, Guillermo ;

Jabbour, Elias ;

Borthakur, Gautam ;

Faderl, Stefan ;

Estrov, Zeev ;

Godley, Lucy ;

Gabrail, Nashat Y. ;

Berdeja, Jesus G. ;

Nadeem, Ahmed ;

Stein, Karen ;

Noble, Yvonne ;

Kassalow, Laurent ;

Kantarjian, Hagop M. .

BLOOD, 2011, 118 (21) :1628-1629

[32] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) [J].

Gasal, E. ;

Pan, C. ;

Tankersley, C. .

LEUKEMIA RESEARCH, 2013, 37 :S166-S167

[33] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study [J].

Valcarcel, David ;

Sanz, Guillermo ;

Ortega, Margarita ;

Nomdedeu, Benet ;

Luno, Elisa ;

Diez-Campelo, Maria ;

Teresa Ardanaz, Maria ;

Pedro, Carmen ;

Montoro, Julia ;

Collado, Rosa ;

Andreu, Rafa ;

Marco, Victor ;

Teresa Cedena, Maria ;

de Paz, Raquel ;

Tormo, Mar ;

Xicoy, Blanca ;

Ramos, Fernando ;

Bargay, Joan ;

Gonzalez, Bernardo ;

Brunet, Salut ;

Antonio Munoz, Juan ;

Gomez, Valle ;

Bailen, Alicia ;

Sanchez, Joaquin ;

Merchan, Brayan ;

del Canizo, Consuelo ;

Vallespi, Teresa .

LANCET HAEMATOLOGY, 2015, 2 (06) :E260-E266

[34] 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program [J].

Musto, Luca Maurillo ;

Spagnoli, Alessandra ;

Gozzini, Antonella ;

Rivellini, Flavia ;

Tatarelli, Caterina ;

Lunghi, Monia ;

Fili, Carla ;

Orciuolo, Enrico ;

Ciuffreda, Lucia ;

Vigna, Ernesto ;

Della Cioppa, Paola ;

Candoni, Anna ;

Ferrero, Dario ;

Palmieri, Salvatore ;

Palumbo, Giuseppe ;

Di Renzo, Nicola ;

Oliva, Esther ;

Sanpaolo, Grazia ;

Pastore, Domenico ;

Tonso, Anna ;

Santagostino, Alberto ;

Rocco, Stefano ;

Villani, Oreste ;

D'Auria, Fiorella ;

D'Arco, Alfonso Maria ;

Gaidano, Gianluca ;

Galimberti, Sara ;

Russo, Domenico ;

Venditti, Adriano ;

Aloe-Spiriti, Maria Antonietta ;

Leone, Giuseppe ;

Santini, Valeria .

BLOOD, 2008, 112 (11) :926-927

[35] BIOSIMILAR ERYTHROPOIETIN ALFA FOR THE THERAPY OF ANEMIA IN "LOWER RISK" MYELODYSPLASTIC SYNDROMES. INTERIM RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF THE "RETE EMATOLOGICA LOMBARDA" (EPOREL) [J].

Pelizzari, A. M. ;

Borlenghi, E. ;

Mariotti, J. ;

Riva, M. ;

Molteni, A. ;

Lambertenghi, D. ;

Passi, A. ;

Orlando, V. ;

Lamorgese, C. ;

Morra, E. .

HAEMATOLOGICA, 2016, 101 :775-775

[36] ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study [J].

Platzbecker, Uwe ;

Germing, Ulrich ;

Giagounidis, Aristoteles ;

Goetze, Katharina ;

Kiewe, Philipp ;

Mayer, Karin ;

Ottman, Oliver ;

Radsak, Markus P. ;

Wolff, Thomas ;

Haase, Detlef ;

Hankin, Monty ;

Wilson, Dawn M. ;

Laadem, Adberrahmane ;

Sherman, Matthew L. ;

Attie, Kenneth M. .

BLOOD, 2014, 124 (21)

[37] Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. [J].

Musto, P ;

Falcone, A ;

Sanpaolo, G ;

Bodenizza, C ;

La Sala, A ;

Carella, AM .

BLOOD, 2003, 102 (11) :327B-328B

[38] Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks. [J].

Paguette, R. ;

Gabrilove, J. ;

Lyons, R. ;

Mushtaq, C. ;

Sekeres, M. ;

Lam, H. ;

Dreiling, L. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :352S-352S

[39] Effectiveness of darbepoetin alfa vs epoetin alfa in patients with anemia resulting from myelodysplastic syndrome (MDS): results of a retrospective cohort study. [J].

Patten, JE ;

Sullivan, T ;

Mun, Y ;

Wallace, J .

PHARMACOTHERAPY, 2005, 25 (03) :468-468

[40] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome [J].

Marcel Merchan, Brayan ;

Ortega, Margarita ;

Jose Llamas-Poyato, Mara ;

Cortes, Montserrat ;

Arnan, Montserrat ;

Cervero, Carlos ;

Montoro, Julia ;

Gimenez, Teresa ;

Lopez, Mara ;

Arenillas, Leonor ;

Valcarcel, David .

BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →